Beta-lactam antibiotics represent a crucial class of antimicrobial agents widely employed in the treatment of bacterial infections. This class includes penicillins, cephalosporins, carbapenems, and monobactams. The hallmark of beta-lactam antibiotics is the presence of a beta-lactam ring in their chemical structure, which plays a pivotal role in their mechanism of action. These antibiotics target bacterial cell walls by inhibiting the synthesis of peptidoglycan, a crucial component for structural integrity. By binding to penicillin-binding proteins (PBPs), beta-lactam antibiotics disrupt the final stages of bacterial cell wall synthesis, leading to cell lysis and death. The versatility of this class of antibiotics is evident in their spectrum of activity against both Gram-positive and Gram-negative bacteria. Beta-lactam antibiotics, especially penicillins, have been instrumental in medical history, revolutionizing the field of infectious disease treatment. Sir Alexander Fleming's discovery of penicillin in 1928 marked a groundbreaking moment, opening the door to the era of antibiotics. Over the years, researchers have developed various derivatives and generations of beta-lactam antibiotics to enhance efficacy and combat bacterial resistance. Despite their effectiveness, the rise of beta-lactamase enzymes, which hydrolyze the beta-lactam ring, poses a significant challenge. To address this issue, combination therapies with beta-lactamase inhibitors have been developed, restoring the efficacy of beta-lactam antibiotics against resistant strains.